Antibiotic Resistance Market worth $18.34 Billion by 2030, page-4

Pivalde...Would be great if we receive positive news from The Fund before the end of 2022 or even before the February, 2023 Nasdaq deadline. I doubt, though, that they are feeling any pressure from Alterity, unfortunately. Couple of questions:1) Some time ago, Alterity announced that their drug development platform discovered/produced over 100+ NEW small molecule drug candidates. Do you think they have done anything with them since then, like apply for patent protection, or would they necessarily have to do clinic work first? 2) Do you feel that any of them have similar or better capabilities (safety & efficacy) than PBT2 & ATH434 which would really set us back with our present pursuits?! 3) Is there any chance that, at some point, Alterity will revisit PBT2 for combatting Neurodegenerative Diseases (e.g. Alzheimer's) or pursue combining PBT2 and ATH434(or some of the newly discovered drugs) to combat certain health afflictions? I realize we obviously don't have the manpower or resources to pursue these potential opportunities as our " plate is full" unless something TRANSFORMATIVE occurs! Let's all hope and pray something wonderful happens in the very near future...